Archive | November, 2015
twin memes II

An Overview of Pharmacologic Management of Chronic Pain.

2016 Jan;100(1):65-79. doi: 10.1016/j.mcna.2015.08.006. Epub 2015 Oct 27. Beal BR1, Wallace MS2. Author information Abstract Patients with chronic pain can be challenging to manage and historically providers have relied on opiates to treat pain. Recent studies have brought into question the safety and efficacy of chronic opiate therapy in the noncancer population. There is a vast […]

PM 1a

Therapeutic Potential of Cannabinoids in Psychosis.

2015 Nov 28. pii: S0006-3223(15)00995-6. doi: 10.1016/j.biopsych.2015.11.018. [Epub ahead of print] Leweke FM1, Mueller JK2, Lange B2, Rohleder C2. Author information Abstract Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly […]

PM 1a

Imaging of Neuroinflammation in Alzheimer’s Disease, Multiple Sclerosis and Stroke: Recent Developments in Positron Emission Tomography.

2015 Nov 28. pii: S0925-4439(15)00350-6. doi: 10.1016/j.bbadis.2015.11.011. [Epub ahead of print] Janssen B1, Vugts DJ2, Funke U3, Molenaar GT3, Kruijer PS4, van Berckel BN2, Lammertsma AA2, Windhorst AD5. Author information Abstract Neuroinflammation is thought to play a pivotal role in many diseases affecting the brain, including Alzheimer’s disease, multiple sclerosis and stroke. Neuroinflammation is characterised predominantly by microglial activation, which can be […]

PM 1a

The long-term functional consequences of acute infectious diarrhea.

2015 Nov 28. [Epub ahead of print] Cocciolillo S1, Collins SM. Author information Abstract PURPOSE OF REVIEW: The study reviews recent publications that build on previous studies showing that acute enteric infection can produce persistent dysfunction in the lower gut (postinfectious irritable bowel syndrome) and proximal gut (postinfectious functional dyspepsia). The review addresses risk factors, the […]

PM 1a

Country break-out session highlights.

2015 Dec;5(6s):31-37. Fazekas F1, Gehring K2, Gallo P3, Lebrun-Frénay C4, Moral E5, Myhr KM6. Author information Abstract Individuals with multiple sclerosis (MS) spasticity present a wide range of symptoms and disability levels that are frequently challenging to manage. At the MS Experts Summit 2015, five country breakout sessions were conducted in parallel, and mainly in the native language, to examine […]

PM 1a

Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants.

 2015 Nov 26;13(6):760-75. Ogawa S, Kunugi H1. Author information Abstract Cannabis and analogs of Δ9-Tetrahydrocannabinol have been used for therapeutic purposes, but their therapeutic use remains limited because of various adverse effects. Endogenous cannabinoids have been discovered, and dysregulation of endocannabinoid signaling is implicated in the pathophysiology of major depressive disorder (MDD). Recently, endocannabinoid hydrolytic enzymes such as […]

PM 1a

Long-Term Data of Efficacy, Safety and Tolerability in a Real Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

 2015 Nov 26. doi: 10.1002/jcph.670. [Epub ahead of print] Paolicelli D1, Direnzo V1, Manni A1, D’Onghia M1, Tortorella C1, Zoccolella S1, Lecce VD1, Iaffaldano A1, Trojano M1. Author information Abstract Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was approved as add-on therapy for spasticity in patients with Multiple Sclerosis (MS). We showed our forty-weeks post-marketing experience regarding efficacy and safety of THC/CBD spray in an Italian […]

PM 1a

Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.

 2015 Nov 26. doi: 10.1111/1440-1681.12518. [Epub ahead of print] Ostadhadi S1,2, Haj-Mirzaian A1,2, Nikoui V1,2, Kordjazy N1,2, Dehpour AR1,2. Author information Abstract Cannabinoid inverse agonists possess antidepressant-like properties, but the mechanism of this action is unknown. Numerous studies reported the interaction between opioid and cannabinoid pathways. In this study, we used acute foot-shock stress in mice to investigate the involvement of opioid […]

PM 1a

The Effect of Medical Marijuana Laws on Body Weight.

 2015 Nov 25. doi: 10.1002/hec.3267. [Epub ahead of print] Sabia JJ1, Swigert J2, Young T1. Author information Abstract This study is the first to examine the effects of medical marijuana laws (MMLs) on body weight, physical wellness, and exercise. Using data from the 1990 to 2012 Behavioral Risk Factor Surveillance System and a difference-in-difference approach, we find that the […]

PM 1a

Δ9-Tetrahydrocannabinol (Δ9-THC) Promotes Neuroimmune-Modulatory MicroRNA Profile in Striatum of Simian Immunodeficiency Virus (SIV)-Infected Macaques.

2015 Nov 25. [Epub ahead of print] Simon L1, Song K2, Vande Stouwe C2, Hollenbach A3, Amedee A4, Mohan M5, Winsauer P6, Molina P7. Author information Abstract Cannabinoid administration before and after simian immunodeficiency virus (SIV)-inoculation ameliorated disease progression and decreased inflammation in male rhesus macaques. Δ9-tetrahydrocannabinol (Δ9-THC) did not increase viral load in brain tissue or produce additive neuropsychological impairment in […]